Acute-phase reactant protein profiles: an aid to monitoring large bowel cancer by CEA and serum enzymes. by Ward, A. M. et al.
Br. J. Cancer (1977) 35, 170
ACUTE-PHASE REACTANT PROTEIN PROFILES: AN AID TO
MONITORING LARGE BOWEL CANCER BY CEA AND SERUM
ENZYMES
A. MILFORD WARD,* E. H. COOPER,t R. TURNER,t J. A. ANDERSONt
AND A. M. NEVILLE**
From *The Protein Reference Unit, Hallamshire Hospital, Sheffield, tDepartment of Experimental
Pathology and Cancer Research and tDepartment ofCommunity Medicine, University ofLeeds,
and **Unit of Human Cancer Biology, The Ludwig Institute of Cancer Research, in conjunction
with the Royal Marsden Hospital, Fulham Road, London SW3 6JB
Received 9 August 1976 Accepted 11 October 1976
Summary.-The profiles of 4 acute-phase reactant proteins (APRPs) (haptoglobin
(HPT)-, a, antitrypsin (AAT), al acid glycoprotein (AGP) and prealbumin (PALB))
have been studied during the evolution of bowel cancer. Serial measurements of
these APRPs can add to the information obtained from measurements of the level of
CEA and hepatic enzymes during the monitoring ofpostoperative patients. There is
considerable stability in the profile in a given individual in health. Rises ofAAT and
AGP are associated with metastases. High levels of HPT may suggest involvement
of the bowel wall by recurrent cancer. PALB levels tend to reflect the nutritional
status. A discriminant function based on the log CEA, AAT and AGP preoperative
blood levels can considerably improve on the predictive value attained using CEA
levels alone.
THERE is now a substantial body of
evidence from Europe and North America
thatsequential measurement oftheplasma
carcinoembryonic antigen (CEA) concen-
trations can provide an earlier warning of
the recurrence and metastasis of large
bowel cancer (see Neville and Cooper,
1976 and Go, 1976 for reviews). How-
ever, this test alone has certainlimitations,
since CEA may not be elevated in primary
tumours, especially Dukes A and B lesions,
orwhenthere is a minimalresidual tumour
load remaining after resection of the pri-
mary tumour. The probable site of the
metastases is not indicated by the level of
CEA, although this omission can be over-
come, at least in part, by the synchronous
measurement of serum enzymes that
reflect disturbances of hepatic function
(Cooper et al., 1975; Munjal et al., 1976;
Schwartz, 1976) but these tests do not
become positive until there is a consider-
able tumour load, as judged by inspection
of the liver at laparotomy (Cooper et al.,
1976a). In a search for other biochemical
tests that might be used to form an array
forthe monitoring ofcolorectal cancer, our
attention has turned to the a globulins.
In common with many forms of cancer,
colorectal cancer often induces a distur-
bance of the a globulins, and an initial
study of the behaviour of haptoglobin, a
member ofthe a globulin group ofplasma
protein (Cooper et al., 1976b), indicated
that the change in the profile of several
acute-phase reactant proteins (APRPs)
warranted further study. In this paper
we report changes in the profile of four
APRPs, measured both in horizontal
studies to relate the change ofprofile with
evolution of the disease in individual
patients, and in vertical studies to relate
the general alterations encountered in
various clinical stages to the natural
history of the cancer and its metastases.
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completely our total experience of CEA,
which is now based on several thousand
estimations in colorectal cancer. It has
been designed, using selected test samples,
to evaluate whether a profile of APRPs
can provide information complimentary
to CEA and hepatic function tests. We
also describe how the application ofa step-
wise logistic discriminant analysis to the
components of the array measured in pre-
operative patients can provide a prog-
nostic index that is more powerful than
CEA alone.
PATIENTS AND METHODS
Patients. One hundred and two patients,
aged 45-92 (mean 68) years, were studied.
The 237 samples of blood tested included 70
taken preoperatively from patients at the
time of their first presentation. The follow-
up samples were selected from our serum
bank, held at -25°C, on the basis of the
known pattern of evolution of the metastatic
cancer, or evidence of potential cure as
indicated by absence of evidence of recur-
rence and a normal CEA for 1-2 years after
resection of the primary cancer. For con-
venience, the material has been stratified with
respect to a number ofclinical and laboratory-
based criteria. Primarv tumours were divid-
ed into: (1) those in which surgery was
apparently successful (Dukes A, B and C)
without any residual disease and patients
have remained tumour free for at least one
year; (2) apparently successful resections that
subsequently developed evidence of meta-
stases during a follow-up of 1-2 years; and (3)
patients in whom the primary lesion was
complicated by overt metastases which varied
considerably in amount from minimal residual
disease undetectable after the wound was
closed to marked indicator lesions, especially
in the liver.
The postoperative samples were grouped
as: (a) tumour-free, in which there was no
evidence ofrecurrence clinically and the CEA
was < 30 ng/ml; (b) suspicious, in which the
CEA was > 30 ng/ml but there was no evi-
dence oftumour detected clinically; (c) pelvic
and peritoneal metastases based on clinical
findings; and (d) hepatic metastases that had
either been observed at laparotomy or diag-
nosed subsequently as the result of a progres-
sive elevation ofCEA, associated with a rising
yglutamyl transpeptidase and 5' nucleotidase.
Methods.-The plasma CEA was measured
using the assay described by Laurence et al.
(1972), the upper limit ofnormal being taken
as 15 ng/ml. A level of 30 ng/ml has been
chosen as the decision point, since a rise above
this value in a postoperative patient carries a
probability of0 95 that there is an underlying
recurrent cancer. Gamma glutamyl trans-
peptidase (GGT) and 5' nucleotidase (NTD)
were measured as described previously
(Cooper et al., 1975).
Haptoglobin (HPT), oil-acid glycoprotein
(AGP) and prealbumin (PALB) were measur-
ed by single radial immunodiffusion, using
antisera and standard preparations obtained
from Behringwerke AG, Marburg/Lahn, W.
Germany. The HPT phenotypes were identi-
fied by electrophoresis on gradient pore poly-
acrylamide gels (Baxter and Rees, 1974).
The correction factors applied were x 0-6 for
Hp 1: 1, x 1-3 for Hp 2: 1 and x 1-5 for
Hp 2: 2. Antitrypsin (AAT) and cerulo-
plasmin (CPL) were measured by automated
immunoprecipitation (Ritchie, 1973), anti-
sera being obtained from Atlantic Antibodies
Inc, Westbrook, Maine (AAT) and Behring-
werke AG (CPL).
The normal range for these plasma pro-
teins in our laboratories is HPT 0-5-2-5 g/l,
AAT 1 8-3-0 g/l, AGP 0-6-10 g/l, PALB
0-2-0-4 g/l and CPL01-0-3 g/l. These ranges
are applicable to a healthy population over
the age of 40 years, but do not necessarily
apply directly to a population weighted in
excess of 65 years, which would more closely
approximate the cancer patients under study
whose median age is 68 years.
Statistical analysis.-Thegrouped data are
expressed as group means and the standard
deviation (s.d.) and standard error (s.e.) of
the mean. The discriminant function for the
separation of patients who remained tumour-
free for at least 1 year after surgery (Group I)
from those who developed metastases after an
apparently curative resection (Group 2) was
derived by logistic discriminant analysis
(Anderson, 1972).
A step-wise approach was taken to the
establishment of the discriminant function.
Thus the potential discriminators were con-
sidered one at a time, and the one (log10 CEA)
which best separated the two groups was
selected. Then the variable which best
assisted logl0 CEA to separate the groups was
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selected. This procedure continued, adding
discriminant variables one at a time until the
extra separation given by the next ' best"
discriminator was no longer statistically
significant, as judged by an asymptotic log-
likelihood ratio test. In the order selected by
this procedure, the discriminant variables
were log1o CEA, cxl-antitrypsin and oil-acid
glycoprotein, and the discriminant function
was estimated to be:
I = 6-2 2-6x-1 16x2 + 1 3X3,
where xi
and x3=
surgery.
= log1o CEA ng/ml, x2 AAT g/l
AGP g/l as measured prior to
RESULTS
Horizontal studies
The behaviour ofthe profile ofAPRPs
in colorectal cancer is best illustrated by
considering their patterns during the
follow-up after surgical treatment of the
primary tumour. The following examples
have been selected to indicate the chrono-
logical change in a battery of proteins
which depicts graphically the events
underlying the larger series that have been
classified into a number of discrete events
in the vertical studies.
Fig. 1 shows the evolution of the
APRPs in a patient who developed
hepatic metastases after an apparent
disease-free interval. Six months prior to
the start of monitoring, the patient had
undergone a curative resection of a Dukes
Cl tumour of the colon. During the
course ofthe studytheCEArosefrom 26 to
125 ng/ml and the GGT was 60 iu/l at the
last reading: subsequently the patient
deteriorated rapidly, developing obvious
clinical signs of hepatic metastases, and
died 4 months after the last set ofmeasure-
ments. At the time of the last reading
there had been no clinical evidence of
metastases.
Fig. 2 shows the stability of the pro-
teins after the 4th month following the
resection of a Dukes B carcinoma of the
colon in a woman aged 56 years. The
first observation was made the day before
surgery. At that time the CEA was
84 ng/ml and all the APRPs were raised.
Subsequently the CEA has remained
10 ng/ml and the APRPs have been
within normal limits.
Fig. 3 demonstrates the pattern of the
APRP profile in a woman aged 72 years
who had a Dukes B tumour of the recto-
sigmoid excised in May 1973, and 9
months later was found to have a local
recurrence that required excision. Sub-
sequently she developed progressive spread
of the tumour in the pelvis and peritoneal
cavity, and died 7 months later. Plasma
HPT
9//
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FIG. 1. Evolution of APRPs during the development of hepatic metastases.
AAT, a antitrypsin; AGP, acid glycoprotein.
HPT, haptoglobin;
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FIG. 2. Stability of the APRP profile in a patient who has remained free of recurrence.
convenience the ceruloplasmin results (CPL) are x 10 to fit the scale.)
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FIG. 3.-The disturbance of the APRP profile caused by recurrent tumour localized to the pelvis
requiring a second resection. (CPL levels x 10.)
CEA gave a preoperative level of 26*8 ng/
ml and 11 ng/ml immediately prior to
excision of the recurrence, with a sub-
sequent rise to 57 ng/ml 2 months prior to
her death.
The APRPs show considerable vari-
ability in the immediate postoperative
period and may take 1-3 months to reach a
stable level, even in patients with potenti-
ally curable tumours whose postoperative
course has been satisfactory. This is
illustrated in Fig. 4. In our analyses we
have excluded observations made in an
immediate postoperative period. By con-
trast the postoperative fall in CEA is
slightly faster, with stable values being
reached 4-6 weeks after curative surgery.
Vertical studies in postoperative patients
The general evolution ofthe changes in
the APRP, GGT and CEA levels are
illustrated in Tables I and II. As indi-
5/
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FIG. 4.,Illustration of the effect of laparotomy and
resection of the rectum. The initial values in this
patient were all within normal limits.
cated inthe methods section, the definition
of a " normal " range is difficult-we
consider that a good useful standard is
best provided by the values found in post-
operative patients in whom prolonged
follow-up has proved that they are cured.
This has been used to select the discrimi-
nant levels adopted in Table II. How-
ever, as emphasized above, it is the tinme
course ofthe patterns that is usually more
informative than the precise value. The
tables are given as they illustrate the
general applicability of the approach and
condense the information into a conveni-
ent form. An analysis of the correlation
matrix of these parameters shows that,
although there are obvious linked trends,
the correlation coefficients are not
> r = 065 in any pair combination,
indicating that the system does not con-
tain redundant information.
Preoperative samples
The distributions of the values of the
components ofthe assay system are shown
in Table III. Due to the marked skew-
ness of the distribution of the CEA and
GGT values in patients with metastatic
cancer, the data have been transformed to
their logarithms. The scatter can be
appreciated from the increased s.d. of the
GGT in the metastatic group compared to
Groups 1 and 2. The mean of the CEA
value rises progressively with the increase
of the severity of the disease. The
distribution of the CEA values in the
three groups is shown in Fig. 5. It will be
observed that the haptoglobin elevation
TABLE I.-Postoperative Patients*
Tumour-free > 2 years
Tumour-free transient
Suspicious (CEA > 30 ng/ml)
Hepatic metastases
Pelvic, peritoneal metastases and
local recurrence
No. of No. of
pts. samples HPT
10 45 2.26t
1-08
0-16
11 18 2-87
1-18
0-28
6 12 3-89
1-80
0-32
14 30 4- 72
1-80
0-32
22 54 3 -38
1 -80
0-23
AAT
2-08
0-52
0-07
2 -35
0-71
0-16
2-92
1-38
0-38
3-74
1-43
0-25
2-57
0-78
0-09
AGP
0-83
0-25
0-03
0-99
0-25
0-06
1-37
0-56
0-12
1-52
0-74
0-13
1-13
0-55
0-08
PALB
0-34
0-12
0-02
0-32
0-14
0-03
0-25
0-09
0-02
0-21
0-12
0-23
0-23
0-09
001
* All values > 3 months after surgery.
t Mean, s.d., s.e. (g/l).
HPT, haptoglobin; AAT, a, antitrypsin; AGP, °cx acid glycoprotein; PALB, prealbumin.
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TABLE II.-Percentage ofPostoperative Samples Suggesting an Abnormality
*Tumour-free > 2 years
Tumour-free transient or
suspicious
Pelvic, peritoneal and
local recurrence
Hepatic metastases
(early, GGT < 100 i.u./l)
late, GGT > 100 i.u./l)
No. of
samples
45
30
GGTt
> 30 IU
11
40
HPT
CEA
> 30ng > 2-5 > 3-5
0 29 22
40 57 47
53 13 26 75 40 25 48 42
20 89 100 95 75 57 25
10 100 100 80 60 80 90
* 60% of these samples came from patients who subsequently developed metastatic cancer. The second
and third sub-sets in Table I have been combined to simulate a population presenting at a follow-up clinic.
t GGT, y glutamyl transpeptidase.
TABLE III. Preoperative Values of the Test Battery
No recurrence
1 year
n = 37
Recurrence
2 years
0= 11
Metastases at
operation
n = 22
log GGT*
1 -3881
0-2817
0-0468
1- 3391
0- 2409
0 - 0738
1 - 5600
0-5323
0- 1073
log CEA*
1 -2543
0-3178
0-0528
1 -7018
0 4950
0-1529
2 - 0859
1 -013
0 - 21260
HPT
3-89t
1 -60
0-26
3 93
1 -40
0-44
4-33
1-69
0-35
AAT
2-65
0-84
0-14
3-30
0-85
0-26
3 -87
1 -03
0-22
AGP
1 -12
0-48
0-08
0-96
0-36
0-11
1 -46
0-89
0-19
PALB
0-18
0-06
0-01
0-17
0-06
0-02
0-17
0-09
0-02
* The antilog of these values gives the geometric mean, not the arithmetic mean (see Fig. 5 for the
distribution of the CEA values).
t Mean, s.d., s.e. (g/l).
can be as marked in patients with a tumour
with a good prognosis as in those in whom
there was advanced metastatic cancer
complicating the primary tumour. In a
4-
5.
WU
2-
:: *P~~~:
- 30
ng/ml
Group I Group I Group m
FIG. 5. Distribution ofthe preoperative log10
CEA values in the three groups ofpatients.
similar fashion, a low prealbumin was a
common finding in all groups of primary
cancers. The low values may reflect a
poor nutritional status, which can com-
plicate either a primary lesion or its meta-
stases. The preoperative values of AAT
and AGP were highest when the primary
tumour was complicated by metastases:
the pattern was similar to that seen when
metastases developed following resection
of the primary tumour.
Fig. 6 shows the extent to which the
logistic discriminant function can separate
the patients in Groups 1 and 2, and Fig. 7
demonstrates the application of the same
function to the CEA, AAT and AGP
values in patients found to have meta-
stases at operation. The predictive value
of these tests is summarized in the follow-
ing statement.
When a " curative" operation was
performed, 18 patients had a negative
index, 8/18 (44%) recurred within 1-2
AAT
> 3-0
5
33
AGP
> 1-0
12
57
PALB
< 0-20
15
30
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FIG. 6. Separation of Groups I and II using
the logistic discriminant.
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FIG. 7.-Application ofthe logistic discrimin-
ant function to the preoperative values of
Group III patients
years, whilst only 3/27 (11%) with a
positive index recurred in the same
period; there were a further 3 patients
with an index of 0, all of whom have
remained without recurrence.
Similarly, of Group III patients, who
had metastatic cancer at operation, vary-
ing from advanced disease to minimal
residual cancer, 19/22 (86%) had a nega-
tive index. The probability of curative
surgery diminished as the negative value
of index increased. An index of > 0 was
associated with a curative operation in
27/33 instances (82%); 5/6 of the failures
with a positive discriminant had indices of
< 0-5. The advantage of the discrimi-
nant over the CEA alone as a prognostic
factor can be seen by comparing the distri-
bution of CEA (Fig. 5) with the corre-
sponding discriminant values (Figs. 6 and
7). The advantage of the system lies in
helping to allocate the CEA up to 100 ng/
ml to the correct group. The value of
GGT did not aid the discriminant, as high
values were always associated with a high
CEA. However, a negative discriminant
with a raised GGT often increases the
probability offindinghepaticmetastasesat
laparotomy.
DISCUSSION
The levels of various APRPs are fre-
quently abnormal in cancer (see Koj, 1974
and Bacchus, 1975 for review). How-
ever, their reaction is non-specific: distur-
bances of various individual APRPs can
be caused by injury, acute and chronic
infection and various inflammatory and
degenerative diseases. In the past, many
vertical studies of individual components
of the spectrum of APRPs have been
studied as potential cancer tests and dis-
carded. Even with the present increased
precision of measurement, the APRPs
alone are not a test for the presence of
cancer. In bowel cancer this is especially
true, as primary cancers may produce
alterations of the APRPs that are closely
mirrored by the responses to inflam-
matory diseases of the large bowel
(Marner, Friborg and Simonsen 1975) so
that the APRP profile does not help in the
differential diagnosis of bowel cancer in
which the CEA is normal or slightly raised,
for this combination can be found in any
of the inflammatory states. Neverthe-
less, gastrointestinal symptoms with a
disturbed APRP profile, with or without
an elevated CEA, are a strong indication
for investigation of the gastrointestinal
tract, and a persistent abnormality of the
protein profile might be taken as an indica-
tion of a need to re-examine the bowel, if
no lesion can be detected on the first x-ray
studies. About 7% ofcolon tumours may
not be detectable at the time of the first
radiological examination (Lauer, Carlson
and Wollaeger, 1965).
The relative stability of the protein
I I - I I I
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profile in a given individual, as long as his
health remains in steady state, is an essen-
tial property that makes protein profiling
useful in cancer monitoring. The present
studies have confirmed this stability,
which was suggested by previous studies
of HPT (Cooper et al., 1976b). Random
measurements of protein profiles after
bowel surgery are of little value, other
than that they may confirm suspicion -of
metastases that have been suggested by an
elevated CEA. The profiling system only
becomes a valuable indicator of tumour
recurrence when it is measured sequenti-
ally. A similar experience has been
reported by others using single or several
APRPs (Mueller, Handschumacher and
Wade, 1971; Vickers, 1974). We have
found thatAPRPs can addto the informa-
tion provided by CEA and liver enzyme
markers for monitoring the chemotherapy
of colorectal cancer (Bullen et al., 1976).
However, the APRPs have the disadvan-
tage ofbeing sensitive to signals produced
by wounded tissues, so that stability may
not be reached for 3 months after major
surgery such as abdominoperineal excision
of the rectum. AAT and AGP are both
increased in metastatic cancer and tend to
be load-dependent. This effect is also
found in other forms of adenocarcinoma
such as breast, stomach and transitional-
cell tumours ofthe bladder (Milford Ward
etal., unpublished data). However, about
14% of the Caucasian population in the
United Kingdom will be of a non-MAAT
phenotype, which results in the levels of
AAT being lower than normal (Cook,
1974).
HPT is a particularly sensitive indi-
cator. High levels may accompany un-
complicated primary bowel cancer, the
levels tend to remain above the normal
range in patients who have had a resec-
tion, and are not influenced by the pre-
sence or absence of a colostomy. We
have the impression, based on 4 patients,
that an unexpected and sustained rise of
HPT after resection of a colorectal cancer
may indicate local recurrence or meta-
stases involving the bowel wall.
PALB was added to the array as it is a
negative reactant, and in longitudinal
studies its slow fall may be the first sign of
deterioration. PALB tends to take sever-
al months to reach its highest level in
patients treated successfully, and also may
be restored to the normal range when
patients respond favourably to chemo-
therapy (Bullen et al., 1976).
The combination of CEA and non-
specific tumour markers may help in the
identification of high-risk patients. It
appears that, using adiscriminant function
based on CEA and APRPs, patients with a
negative discriminant index have a worse
prognosis than those in which itispositive.
This is mainly, but not wholly, due to the
value of the CEA. The ability of the
discriminant to separate the probable
failures from the probable successes in
patients where the CEA is < 100 ng/ml is
the main advantage of the system. It is
well established that CEA values > 100
ng/ml carry a poor prognosis.
Current experience of CEA tests, and
their use in combination with non-specific
indicators, suggests that 2-3-monthly
bloodtests are neededifthe systemisgoing
to be given a real chance to provide early
warning. Obviously, high risk patients
should be given priority, especially if the
clinician intends to use the information as
a possible indication for additional thera-
py, whilst the tumour load is low and the
patient is in a good general state ofhealth.
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